• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    Biologic License Application (BLA): 761343
    Company: ALVOTECH USA INC
    • Email

    Products on BLA 761343

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    SELARSDI USTEKINUMAB-AEKN 45MG/0.5ML INJECTABLE;INJECTION Prescription None No No
    SELARSDI USTEKINUMAB-AEKN 90MG/ML INJECTABLE;INJECTION Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 761343

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/16/2024 ORIG-1 Approval N/A Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761343s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761343Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761343Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    10/18/2024 SUPPL-3 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761343Orig1s001, 003ltr.pdf
    10/18/2024 SUPPL-1 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761343Orig1s001, 003ltr.pdf

    Labels for BLA 761343

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    04/16/2024 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761343s000lbl.pdf
    Get the next $ALVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    12/9/2025$5.00Underweight
    Barclays
    11/4/2025$8.00Buy → Hold
    Deutsche Bank
    10/14/2025$14.00Equal-Weight → Overweight
    Morgan Stanley
    9/23/2025$14.00Hold → Buy
    Deutsche Bank
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    More analyst ratings

    $ALVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

    REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the "Offering") of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deductin

    6/18/26 5:51:41 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

    REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the "Offering") of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up

    6/15/26 11:59:43 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

    REYKJAVIK, Iceland, June 15, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the "Offering"). In addition, Alvotech expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when

    6/15/26 4:01:00 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Alvotech with a new price target

    Barclays initiated coverage of Alvotech with a rating of Underweight and set a new price target of $5.00

    12/9/25 8:42:22 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Alvotech from Buy to Hold and set a new price target of $8.00

    11/4/25 7:41:39 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Alvotech from Equal-Weight to Overweight and set a new price target of $14.00

    10/14/25 8:33:59 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    SEC Filings

    View All

    SEC Form 6-K filed by Alvotech

    6-K - Alvotech (0001898416) (Filer)

    6/18/26 12:32:47 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Alvotech

    6-K - Alvotech (0001898416) (Filer)

    6/16/26 7:47:18 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Alvotech

    424B5 - Alvotech (0001898416) (Filer)

    6/16/26 5:26:18 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Leadership Updates

    Live Leadership Updates

    View All

    Alvotech announces planned CEO succession and leadership transition

     - Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company's inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capac

    1/6/26 7:15:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

    REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm. Patrik Ling has more than 25 years of experience in the life-science industry. Most recently he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech. He began his career in marketing and sales of pharmaceuticals, before transitioning to the financial sector, where he was a portfolio manager and equity analyst focusing on the life-s

    8/20/25 6:05:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

    REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in finance and corporate leadership. She has held senior roles across a range of industries, including banking, food technology, transportation, and healthcare. Linda will be based in Iceland. Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down to spend more time in the U.S. and prioritize time with

    7/10/25 4:40:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Financials

    Live finance-specific insights

    View All

    Alvotech to Report Financial Results for the First Quarter of 2026

    REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST). To listen to the webcast, please register here: Q1 2026 webcast registrationTo participate in the Q&A, please register here: Q1 2026 conference call registration Slides and other material will be made

    4/24/26 8:30:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

    REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To listen to the webcast, register here: Q4 and Full Year 2025 webcast registrationTo participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration Slid

    3/4/26 3:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

    Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D investments to accelerate pipeline expansion and lower licensing revenues in the period. Phasing of revenues in 2024 resulted in Q2 being the best quarter of the year, while Q4 of is expected to be the best quarter of 2025  

    11/12/25 4:40:00 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alvotech

    SC 13G/A - Alvotech (0001898416) (Subject)

    11/6/24 1:51:59 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Alvotech

    SC 13D/A - Alvotech (0001898416) (Subject)

    7/3/24 5:31:12 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Alvotech (Amendment)

    SC 13G/A - Alvotech (0001898416) (Subject)

    2/14/24 12:14:38 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care